The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation
Open accessAbstract
Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population. Sarcopenia is a main indicator of adverse outcomes in this population, including poor quality of life, hepatic decompensation, mortality in patients with cirrhosis evaluated for liver transplantation (LT), longer hospital and intensive care unit stay, higher incidence of infection following LT, and higher overall health care cost. Although it is clear that muscle mass is an important predictor of LT outcomes, many questions remain, including the best modality for assessing muscle mass, the optimal cut‐off values for sarcopenia, the ideal timing and frequency of muscle mass assessment, and how to best incorporate the concept of sarcopenia into clinical decision making. For these reasons, we assembled a group of experts to form the North American Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature to address these outstanding questions regarding sarcopenia in LT. We believe sarcopenia assessment should be considered in all patients with cirrhosis evaluated for liver transplantation. Skeletal muscle index (SMI) assessed by computed tomography constitutes the best‐studied technique for assessing sarcopenia in patients with cirrhosis. Cut‐off values for sarcopenia, defined as SMI < 50 cm 2/m 2 in male and < 39 cm 2/m 2 in female patients, constitute the validated definition for sarcopenia in patients with cirrhosis. Conclusion: The management of sarcopenia requires a multipronged approach including nutrition, exercise, and additional pharmacological therapy as deemed necessary. Future studies should evaluate whether recovery of sarcopenia with nutritional management in combination with an exercise program is sustainable as well as how improvement in muscle mass might be associated with improvement in clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601 · cited 4×
“9) Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia.”
InfluentialSarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 4×
“9) Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia.”
InfluentialEpidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 8×
“Sarcopenia was initially defined as age-related loss of skeletal muscle(7) but has since been expanded to reflect low muscle mass leading to negative effects on physical performance and clinical outcomes across a broad range of disease states outside of geriatric populations.”
InfluentialPrado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Shen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692 · cited 1×
“When assessing sarcopenia by SMI on an abdominal CT scan, there does not appear to be a large difference between measurements at L3 versus L4 vertebra (25).”
Welcome to the ICD‐10 code for sarcopenia
Anker, S. D., Morley, J. E., & von Haehling, S. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12147 · Cited by 983
Sarcopenia from mechanism to diagnosis and treatment in liver disease
Dasarathy, S., & Merli, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.040 · Cited by 608
Self-citationMontano-Loza, A. J., Angulo, P., Meza-Junco, J., Prado, C. M. M., Sawyer, M. B., Beaumont, C., Esfandiari, N., Ma, M., & Baracos, V. E. (2016) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12039 · Cited by 512 · cited 1×
“Sarcopenic obesity can be present in 20%-40% of LT candidates with cirrhosis.(49,50) Patients with sarcopenia are more likely to be obese, and those with sarcopenic obesity are more likely to have nonalcoholic fatty liver disease as the etiology of liver disease.”
van Vugt, J. L. A., Levolger, S., de Bruin, R. W. F., van Rosmalen, J., Metselaar, H. J., & IJzermans, J. N. M. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13732 · Cited by 361
Berzigotti, A., Albillos, A., Villanueva, C., Genescá, J., Ardevol, A., Augustín, S., Calleja, J. L., Bañares, R., García‐Pagán, J. C., Mesonero, F., et al. (2017) · Hepatology · doi:10.1002/hep.28992 · Cited by 334 · cited 1×
“Berzigotti et al, 2017 (74) ONCT Aerobic & resistance (16 weeks) kCal reduction BIA lean mass 60 NA HVPG and body weight 56.”
Cited by
Lai, J. C., Tandon, P., Bernal, W., Tapper, E. B., Ekong, U., Dasarathy, S., & Carey, E. J. (2021) · Hepatology · doi:10.1002/hep.32049 · Cited by 742
Self-citationSarcopenia and frailty in decompensated cirrhosis
Tandon, P., Montano-Loza, A. J., Lai, J. C., Dasarathy, S., & Merli, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.025 · Cited by 408
Self-citationAdverse muscle composition predicts all‐cause mortality in the UK Biobank imaging study
Linge, J., Petersson, M., Forsgren, M. F., Sanyal, A. J., & Dahlqvist Leinhard, O. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12834 · Cited by 108
Linge, J., Ekstedt, M., & Dahlqvist Leinhard, O. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2020.100197 · Cited by 98
AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review
Patton, H., Heimbach, J., & McCullough, A. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.034 · Cited by 97
Nachit, M., De Rudder, M., Thissen, J., Schakman, O., Bouzin, C., Horsmans, Y., Vande Velde, G., & Leclercq, I. A. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12646 · Cited by 82
Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD
Linge, J., Nasr, P., Sanyal, A. J., Dahlqvist Leinhard, O., & Ekstedt, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100663 · Cited by 42
Nonalcoholic fatty liver disease and sarcopenia: Where do we stand?
Mikolasevic, I., Pavic, T., Filipec Kanizaj, T., Bender, D. V., Domislovic, V., & Krznaric, Z. (2020) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2020/8859719 · Cited by 30
Metadata
- Authors
- Carey, E. J., Lai, J. C., Sonnenday, C., Tapper, E. B., Tandon, P., Duarte‐Rojo, A., Dunn, M. A., Tsien, C., Kallwitz, E. R., Ng, V., Dasarathy, S., Kappus, M., Bashir, M. R., & Montano‐Loza, A. J.
- Venue
- Hepatology
- Published
- 2019-08-19
- Volume
- 70
- Issue
- 5
- Pages
- 1816-1829
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2950388170
- Cited by
- 246
- References
- 14
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.